You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 58 No. 12, December 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (101)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Cerebrovascular Disease
 •Stroke
 •Alert me on articles by topic

Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke

Houston Experience 1996 to 2000

James C. Grotta, MD; W. Scott Burgin, MD; Ashraf El-Mitwalli, MD; Megan Long; Morgan Campbell, MD; Lewis B. Morgenstern, MD; Marc Malkoff, MD; Andrei V. Alexandrov, MD

Arch Neurol. 2001;58:2009-2013.

Context  Intravenous tissue-type plasminogen activator (tPA) therapy using the National Institute of Neurological Disorders and Stroke criteria has been given with variable safety to less than 5% of the patients who have ischemic strokes nationwide. Our center is experienced in treating large numbers of stroke patients with intravenous tPA.

Objective  To report our total 4-year experience in the treatment of consecutive patients who had an ischemic stroke.

Design  Prospective inception cohort registry of all patients seen by our stroke team and an additional retrospective medical record review of all patients treated between January 1, 1996, and June 1, 2000.

Setting  A veteran stroke team composed of fellows and stroke-specialty faculty servicing 1 university and 3 community hospitals in a large urban setting.

Patients  Consecutive patients with ischemic stroke treated within the first 3 hours of symptom onset.

Intervention  According to the National Institute of Neurological Disorders and Stroke protocol, 0.9 mg/kg of intravenous tissue-type plasminogen activator was administered.

Main Outcome Measures  Number and proportion treated, patient demographics, time to treatment, hemorrhage rates, and clinical outcome.

Results  A total of 269 patients were treated between January 1, 1996, and June 1, 2000. Their mean age was 68 years (age range, 24-93 years); 48% were women. This represented 9% of all patients admitted with symptoms of cerebral ischemia at our most active hospital (over the final 6 months, 13% of all patients with symptoms of cerebral ischemia and 15% of all acute ischemic stroke patients). Before treatment the mean ± SD National Institutes of Health Stroke Scale (NIHSS) score was 14.4 ± 6.1 points (median, 14 points; range, 4-33 points). A tPA bolus was given at 137 minutes (range, 30-180 minutes); 28% of the patients were treated within 2 hours. The mean door-to-needle time was 70 minutes (range, 10-129 minutes). The symptomatic intracerebral hemorrhage rate was 5.6% of those patients with a second set of brain scans (4.5% of all patients), with a declining trend from 1996 to 2000. Protocol violations were found in 13% of all patients; the symptomatic intracerebral hemorrhage rate in these patients was 15%. At 24 hours, the NIHSS score was 10 ± 8 points (median, 8 points; range, 0-36 points). In-hospital mortality was 15% and the patients' discharge NIHSS scores were 7 ± 7 points (median, 3 points; range, 0-35 points).

Conclusions  Intravenous tPA therapy can be given to up to 15% of the patients with acute ischemic stroke with a low risk of symptomatic intracerebral hemorrhage. Successful experience with intravenous tPA therapy depends on the experience and organization of the treating team and adherence to published guidelines.


From the Stroke Treatment Team, University of Texas–Houston Medical School.


RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(12):2078-2079.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

In-Hospital Stroke Treated With Intravenous Tissue Plasminogen Activator
Masjuan et al.
Stroke 2008;39:2614-2616.
ABSTRACT | FULL TEXT  

National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate
Kleindorfer et al.
Stroke 2008;39:924-928.
ABSTRACT | FULL TEXT  

Commentary on NICE guidelines for alteplase for the treatment of acute ischaemic stroke
Lindley
Heart 2007;93:1617-1618.
FULL TEXT  

A Randomized, Controlled Trial to Teach Middle School Children to Recognize Stroke and Call 911: The Kids Identifying and Defeating Stroke Project
Morgenstern et al.
Stroke 2007;38:2972-2978.
ABSTRACT | FULL TEXT  

REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Broderick et al.
Circulation 2007;116:e391-e413.
ABSTRACT | FULL TEXT  

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Broderick et al.
Stroke 2007;38:2001-2023.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Adams et al.
Circulation 2007;115:e478-e534.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Adams et al.
Stroke 2007;38:1655-1711.
ABSTRACT | FULL TEXT  

January 23 Highlight and Commentary: Using tPA for acute stroke in a rural setting
Lyden
Neurology 2007;68:247-247.
FULL TEXT  

Using tPA for acute stroke in a rural setting
Edwards
Neurology 2007;68:292-294.
ABSTRACT | FULL TEXT  

An Expedited Code Stroke Protocol Is Feasible and Safe
Sattin et al.
Stroke 2006;37:2935-2939.
ABSTRACT | FULL TEXT  

Early stroke care in Italy--a steep way ahead: an observational study.
Citerio et al.
Emerg. Med. J. 2006;23:608-611.
ABSTRACT | FULL TEXT  

Comparison of Tissue Plasminogen Activator Administration Management Between Telestroke Network Hospitals and Academic Stroke Centers: The Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany
Audebert et al.
Stroke 2006;37:1822-1827.
ABSTRACT | FULL TEXT  

Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) * Supplemental Appendix 2
Yamaguchi et al.
Stroke 2006;37:1810-1815.
ABSTRACT | FULL TEXT  

IV tissue plasminogen activator use in acute stroke: Experience from a statewide registry
Deng et al.
Neurology 2006;66:306-312.
ABSTRACT | FULL TEXT  

Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients: An Analysis of the Nationwide Inpatient Sample 1999 to 2002
Bateman et al.
Stroke 2006;37:440-446.
ABSTRACT | FULL TEXT  

REACH: Clinical Feasibility of a Rural Telestroke Network
Hess et al.
Stroke 2005;36:2018-2020.
ABSTRACT | FULL TEXT  

Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke
Qureshi et al.
Neurology 2005;64:2115-2120.
ABSTRACT | FULL TEXT  

Improved Quality of Stroke Care for Hospitalized Medicare Beneficiaries in Michigan
Jacobs et al.
Stroke 2005;36:1227-1231.
ABSTRACT | FULL TEXT  

Acute Stroke Care in the US: Results from 4 Pilot Prototypes of the Paul Coverdell National Acute Stroke Registry
The Paul Coverdell Prototype Registries Writing Gr
Stroke 2005;36:1232-1240.
ABSTRACT | FULL TEXT  

Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study
Hill et al.
CMAJ 2005;172:1307-1312.
ABSTRACT | FULL TEXT  

Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association's Task Force on the Development of Stroke Systems
Task Force Members et al.
Stroke 2005;36:690-703.
FULL TEXT  

Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association's Task Force on the Development of Stroke Systems
Schwamm et al.
Circulation 2005;111:1078-1091.
FULL TEXT  

Prioritizing interventions to improve rates of thrombolysis for ischemic stroke
California Acute Stroke Pilot Registry (CASPR) Inv
Neurology 2005;64:654-659.
ABSTRACT | FULL TEXT  

tPA by telephone: Extending the benefits of a comprehensive stroke center
Frey et al.
Neurology 2005;64:154-156.
ABSTRACT | FULL TEXT  

Hourly Blood Pressure Monitoring After Intravenous Tissue Plasminogen Activator for Ischemic Stroke: Does Everyone Need It?
Aiyagari et al.
Stroke 2004;35:2326-2330.
ABSTRACT | FULL TEXT  

Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data
Graham
Stroke 2003;34:2847-2850.
ABSTRACT | FULL TEXT  

Expanded Modes of Tissue Plasminogen Activator Delivery in a Comprehensive Stroke Center Increases Regional Acute Stroke Interventions
Rymer et al.
Stroke 2003;34 :e58-e60.
ABSTRACT | FULL TEXT  

Impact of Establishing a Primary Stroke Center at a Community Hospital on the Use of Thrombolytic Therapy: The NINDS Suburban Hospital Stroke Center Experience
Lattimore et al.
Stroke 2003;34 :e55-e57.
ABSTRACT | FULL TEXT  

Pilot Dose-Escalation Study of Caffeine Plus Ethanol (Caffeinol) in Acute Ischemic Stroke
Piriyawat et al.
Stroke 2003;34:1242-1245.
ABSTRACT | FULL TEXT  

Pre- and In-Hospital Delays From Stroke Onset to Intra-arterial Thrombolysis
Nedeltchev et al.
Stroke 2003;34:1230-1234.
ABSTRACT | FULL TEXT  

Quality Improvement and Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: A Cleveland Update
Katzan et al.
Stroke 2003;34:799-800.
ABSTRACT | FULL TEXT  

Emerging Therapies for Acute Ischemic Stroke: New Therapies on Trial
Fisher and Brott
Stroke 2003;34:359-361.
FULL TEXT  

Analysis of the Safety and Efficacy of Intra-Arterial Thrombolytic Therapy in Ischemic Stroke
Lisboa et al.
Stroke 2002;33:2866-2871.
ABSTRACT | FULL TEXT  

Acute Stroke Care in Illinois: A Statewide Assessment of Diagnostic and Treatment Capabilities * Editorial Comment: A Statewide Assessment of Diagnostic and Treatment Capabilities
Ruland et al.
Stroke 2002;33:1334-1340.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.